Competitive PressuresThere are risks of QTRX falling behind in the Alzheimer's diagnostics market, with competitors already obtaining or planning FDA approvals.
Integration RisksThe AKYA-QTRX deal is expected to close, but integration risks and financial challenges remain concerning.
Revenue DeclineTotal revenue of $24.5M fell short of already lowered expectations, with significant declines in both academic and pharma sectors.